Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study.
Journal
Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
accepted:
31
08
2021
pubmed:
20
9
2021
medline:
2
10
2021
entrez:
19
9
2021
Statut:
ppublish
Résumé
The efficacy of biological therapies used for the treatment of chronic plaque psoriasis can be influenced by numerous variables including body mass index (BMI). This study aimed to evaluate the impact of BMI on the short-term and long-term efficacy of biological therapies in clinical practice and to identify the best therapeutic options in obese patients (BMI ≥ 30 kg/m A multicentric retrospective study was conducted in patients who initiated a biological therapy during the period January 2006-December 2019. The proportion of patients achieving a 90% improvement of baseline Psoriasis Area and Severity Index at weeks 12 and 24 was calculated also recording the 12- and 24-month drug survival as a measure of long-term efficacy, performing multivariate analyses to assess the impact of different variables. Five hundred and four patients with psoriasis were included. After 12 and 24 weeks, the proportion of patients achieving a 90% improvement of baseline Psoriasis Area and Severity Index response was higher in patients with a BMI < 30 kg/m Obesity (BMI ≥ 30 kg/m
Sections du résumé
BACKGROUND
BACKGROUND
The efficacy of biological therapies used for the treatment of chronic plaque psoriasis can be influenced by numerous variables including body mass index (BMI).
OBJECTIVE
OBJECTIVE
This study aimed to evaluate the impact of BMI on the short-term and long-term efficacy of biological therapies in clinical practice and to identify the best therapeutic options in obese patients (BMI ≥ 30 kg/m
METHODS
METHODS
A multicentric retrospective study was conducted in patients who initiated a biological therapy during the period January 2006-December 2019. The proportion of patients achieving a 90% improvement of baseline Psoriasis Area and Severity Index at weeks 12 and 24 was calculated also recording the 12- and 24-month drug survival as a measure of long-term efficacy, performing multivariate analyses to assess the impact of different variables.
RESULTS
RESULTS
Five hundred and four patients with psoriasis were included. After 12 and 24 weeks, the proportion of patients achieving a 90% improvement of baseline Psoriasis Area and Severity Index response was higher in patients with a BMI < 30 kg/m
CONCLUSIONS
CONCLUSIONS
Obesity (BMI ≥ 30 kg/m
Identifiants
pubmed: 34537921
doi: 10.1007/s40261-021-01080-z
pii: 10.1007/s40261-021-01080-z
pmc: PMC8481196
doi:
Substances chimiques
Ustekinumab
FU77B4U5Z0
Etanercept
OP401G7OJC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
917-925Informations de copyright
© 2021. The Author(s).
Références
J Eur Acad Dermatol Venereol. 2011 Sep;25(9):1007-11
pubmed: 21492252
Pharmacol Res. 2008 Apr;57(4):290-5
pubmed: 18400510
J Invest Dermatol. 2009 Jun;129(6):1339-50
pubmed: 19322214
Diabetes Metab. 2004 Feb;30(1):13-9
pubmed: 15029093
Dermatologica. 1978;157(4):238-44
pubmed: 357213
Dermatol Ther (Heidelb). 2020 Jun;10(3):431-447
pubmed: 32200512
Br J Dermatol. 2008 Sep;159(4):895-902
pubmed: 18616778
Pain. 2012 Feb;153(2):265-268
pubmed: 22055553
J Dermatol. 2018 Sep;45(9):1130-1134
pubmed: 30004583
Dermatology. 2018;234(1-2):1-12
pubmed: 30300876
Dermatology. 2008;217(4):365-73
pubmed: 18810241
Curr Rheumatol Rep. 2018 May 30;20(7):43
pubmed: 29846817
J Invest Dermatol. 2005 Jul;125(1):61-7
pubmed: 15982303
J Am Acad Dermatol. 2008 Mar;58(3):443-6
pubmed: 18083274
J Eur Acad Dermatol Venereol. 2017 Feb;31(2):304-311
pubmed: 27324646
J Biopharm Stat. 2018;28(4):645-667
pubmed: 28886277
Br J Dermatol. 2013 May;168(5):1124-7
pubmed: 23320916
J Am Acad Dermatol. 2014 Jul;71(1):133-40
pubmed: 24709272
Proc Nutr Soc. 2012 May;71(2):332-8
pubmed: 22429824
J Dermatolog Treat. 2020 Aug;31(5):476-483
pubmed: 31557063
Br J Dermatol. 2008 Aug;159(2):342-50
pubmed: 18547319
Br J Dermatol. 2019 Sep;181(3):450-458
pubmed: 30729500
J Clin Invest. 1997 Dec 1;100(11):2777-82
pubmed: 9389742
J Clin Epidemiol. 1995 Dec;48(12):1503-10
pubmed: 8543964
J Dermatolog Treat. 2019 Aug;30(5):424-429
pubmed: 30244618
Int J Obes (Lond). 2015 Aug;39(8):1197-202
pubmed: 25920774
J Am Acad Dermatol. 2018 Jul;79(1):104-109.e8
pubmed: 29548945
Br J Dermatol. 2020 Aug;183(2):294-302
pubmed: 32124442
Sci Rep. 2018 Oct 30;8(1):16068
pubmed: 30375427
Br J Dermatol. 2008 Sep;159(4):820-6
pubmed: 18637894
J Invest Dermatol. 2015 Nov;135(11):2632-2640
pubmed: 26053050
Circ Res. 1998 Nov 16;83(10):1059-66
pubmed: 9815153
J Am Acad Dermatol. 2019 Jul;81(1):273-275
pubmed: 30790602
J Am Acad Dermatol. 2006 Nov;55(5):829-35
pubmed: 17052489
Am J Clin Dermatol. 2018 Feb;19(1):1-13
pubmed: 29080066
Am J Clin Dermatol. 2021 Jul;22(4):567-579
pubmed: 33786754
Patient Prefer Adherence. 2020 Mar 09;14:517-527
pubmed: 32210539
Am J Manag Care. 2016 Jun;22(7 Suppl):s176-85
pubmed: 27356115
Joint Bone Spine. 2019 Mar;86(2):173-183
pubmed: 29635017
Am J Clin Nutr. 2008 Nov;88(5):1242-7
pubmed: 18996858
Rheumatology (Oxford). 2016 Dec;55(12):2191-2199
pubmed: 27651526
Nutr Diabetes. 2012 Dec 03;2:e54
pubmed: 23208415
Arch Dermatol. 2005 Dec;141(12):1527-34
pubmed: 16365253
N Engl J Med. 2014 Jul 24;371(4):326-38
pubmed: 25007392
J Dermatolog Treat. 2014 Feb;25(1):73-4
pubmed: 23621374
J Clin Invest. 2003 Dec;112(12):1796-808
pubmed: 14679176
Actas Dermosifiliogr. 2014 Jan-Feb;105(1):31-44
pubmed: 23177976
Int J Mol Sci. 2019 Mar 23;20(6):
pubmed: 30909615
Diabetes. 2006 Jun;55(6):1537-45
pubmed: 16731815
Ann Rheum Dis. 2014 Jun;73(6):1157-62
pubmed: 23771989